Page last updated: 2024-12-06
sulfatroxazole
Description
Sulfatroxazole is a sulfonamide antibiotic that was once widely used for the treatment of bacterial infections, but its use has declined due to the emergence of resistance. It is a synthetic compound that works by inhibiting the synthesis of dihydrofolic acid, an essential precursor for the synthesis of purines and nucleic acids in bacteria. Sulfatroxazole is typically administered orally and is well absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted in the urine. Sulfatroxazole is effective against a wide range of gram-positive and gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. However, it has limited activity against Pseudomonas aeruginosa and other resistant organisms. Sulfatroxazole is still used for the treatment of certain infections, such as urinary tract infections and otitis media, but it is often used in combination with other antibiotics to improve efficacy. It is also used to prevent infections in people who are at risk, such as those who have had surgery or have a weakened immune system. Sulfatroxazole is available in a variety of formulations, including tablets, capsules, suspensions, and intravenous solutions. Sulfatroxazole is generally well tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, and allergic reactions. In some cases, it can also cause more serious side effects such as liver damage, blood disorders, and Stevens-Johnson syndrome. Sulfatroxazole is not recommended for use in pregnant women or breastfeeding mothers. '
```
sulfatroxazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 31771 |
| CHEMBL ID | 26630 |
| SCHEMBL ID | 93862 |
| MeSH ID | M0139178 |
Synonyms (28)
| Synonym |
|---|
| bdbm50034433 |
| 4-amino-n-(4,5-dimethyl-isoxazol-3-yl)-benzenesulfonamide |
| CHEMBL26630 , |
| sulfatroxazole |
| 4-amino-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide |
| n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamide |
| n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamid |
| unii-zxc0pt8ffs |
| sulfatroxazol [inn-spanish] |
| 23256-23-7 |
| sulfatroxazolum [inn-latin] |
| einecs 245-530-5 |
| sulfatroxazolum |
| sulfatroxazol |
| n(sup 1)-(4,5-dimethyl-3-isoxazolyl)sulfanilamide |
| sulfatroxazole [inn:ban] |
| zxc0pt8ffs , |
| SCHEMBL93862 |
| sulfatroxazole [mart.] |
| sulfatroxazole [inn] |
| DTXSID20177829 |
| BCP24928 |
| 4,5-dimethyl-3-sulfanilamidoisoxazole; isosulfafurazole; n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamide |
| Q27295939 |
| AT25048 |
| YAA25623 |
| 4-amino-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzene-1-sulfonamide |
| n1-(4,5-imethyl-3-isoxazolyl)sulfanilamide |
Research Excerpts
Bioavailability
Dosage Studied
Protein Targets (1)
Inhibition Measurements
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID66184 | Displacement of [125 I] ET-1 from rat aortic smooth muscle A7r5 cells transfected with Endothelin A receptor | 2000 | Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
| Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist. |
| AID66057 | Antagonism of [125 I]ET-1 binding to the rat endothelin receptor in vascular smooth muscle VSM-A10 cells. | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
| Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists. |
| AID180489 | Tested for antagonistic activity against ET-1 induced increase in intracellular [Ca2+] in VSM-A10 cells. | 1995 | Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
| Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists. |
| AID66201 | Inhibition of [125I]endothelin-l binding to endothelin A receptor of rat thoracic aorta smooth muscle cells | 1995 | Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
| Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors. |
| AID66699 | Binding affinity towards displacement of [125 I] ET-3 from COS-7 cells transfected with porcine Endothelin B receptor. | 2000 | Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
| Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist. |
| AID493017 | Wombat Data for BeliefDocking | 2000 | Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
| Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.85 (24.57) | | Research Supply Index | 2.56 (2.92) | | Research Growth Index | 4.42 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |